Clinical Research Directory

Inclusion: * Age 18-85 * Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH) * SAH attributed to ruptured cerebral aneurysm * Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space * World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization * Onset of symptoms of aSAH (ictus) occurred \<72 hours prior to presentation * If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment * All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment * Participant can be randomized within 48 hours of aneurysm treatment * Participant or participant's legally-authorized representative (LAR) has provided documented informed consent Exclusion: * Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm * Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment * Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern * Uncontrollable hypertension (\>180 systolic and/or \>110 diastolic) that is not correctable prior to enrollment * Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days) * A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion * New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT * Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase) * Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation * Thrombocytopenia (platelet count \<100,000/microliter (µL) assuming clumping is ruled out * Allergy or intolerance to tirofiban * Pregnant or lactating * Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute \[ml/min\]) or acute kidney injury (AKI) at study screening. AKI is defined as: i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter \[μmol/L\] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours